The effects of TNF-α on GLP-1-stimulated plasma glucose kinetics

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages E616-E622

  Lehrskov Schmidt, Louise ^a   Lehrskov Schmidt, Lars ^a   Nielsen, Signe T ^a   Holst, Jens J ^b   Møller, Kirsten ^a,b   Solomon, Thomas P J ^a,c  

^a Capital Region   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BODY MASS; BODY TEMPERATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG EFFECT; DRUG MEGADOSE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INSULIN BLOOD LEVEL; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT; BLOOD; DRUG EFFECTS; KINETICS; METABOLISM;

ADULT; BLOOD GLUCOSE; BODY TEMPERATURE; C-PEPTIDE; CROSS-OVER STUDIES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTERLEUKIN-6; KINETICS; MALE; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84927615412     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4244     Document Type: Article

References (25)

1. Thijs LG, Hack CE. Time course of cytokine levels in sepsis. Intensive Care Med. 1995;21(suppl 2):S258-S263.
2. Deane AM, Horowitz M. Dysglycaemia in the critically ill-significance and management. Diabetes Obes Metab. 2013;15(9):792-801.
3. Nielsen ST, Lehrskov-Schmidt L, Krogh-Madsen R, et al. Tumour necrosis factor-α infusion produced insulin resistance but no change in the incretin effect in healthy volunteers. Diabetes Metab Res Rev. 2013;29(8):655-663.
4. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130(1):43-52.
5. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54(10):2939-2945.
6. Dunger A, Cunningham JM, Delaney CA, et al. Tumor necrosis factor-α and interferon-γ inhibit insulin secretion and cause DNA damage in unweaned-rat islets. Extent of nitric oxide involvement. Diabetes. 1996;45(2):183-189.
7. Zhang S, Kim KH. TNF-α inhibits glucose-induced insulin secretion in a pancreatic β-cell line (INS-1). FEBS Lett. 1995;377(2):237-239.
8. Ibfelt T, Fischer CP, Plomgaard P, van Hall G, Pedersen BK. The acute effects of low-dose TNF-α on glucose metabolism and β-cell function in humans. Mediators Inflamm. 2014;2014:295478.
9. Combes J, Borot S, Mougel F, Penfornis A. The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients. Diabetes Obes Metab. 2011;13(2):118-129.
10. Nielsen ST, Krogh-Madsen R, Moller K. Glucose metabolism in critically ill patients: are incretins an important player? [published online September 23, 2013]. J Intensive Care Med. doi:10.1177/0885066613503291.
11. Deane AM, Summers MJ, Zaknic AV, et al. Exogenous glucagonlike peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type 2 diabetes. Crit Care. 2011;15(1):R35.
12. Deane AM, Chapman MJ, Fraser RJ, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med. 2010;38(5):1261-1269.
13. Galiatsatos P, Gibson BR, Rabiee A, et al. The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. Crit Care Med. 2014;42(3):638-645.
14. Yang H, Egan JM, Wang Y, et al. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol. 1998;275(3 Pt 1):C675-C683.
15. Green CJ, Henriksen TI, Pedersen BK, Solomon TP. Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PLoS One. 2012;7(8):e44284.
16. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology. 2009;150(3):1155-1164.
17. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007;293(5):E1289-E1295.
18. Yousef AA, Amr YM, Suliman GA. The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-α in critically ill patients: a prospective observational study. Crit Care. 2010;14(2):R33.
19. Oehlke J, Brudel M, Blasig IE. Benzoylation of sugars, polyols and amino acids in biological fluids for high-performance liquid chromatographic analysis. J Chromatogr B Biomed Appl. 1994;655(1):105-111.
20. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide I in humans. Diabetes. 1994;43(4):535-539.
21. Krogh-Madsen R, Plomgaard P, Moller K, Mittendorfer B, Pedersen BK. Influence of TNF-α and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab. 2006;291(1):E108-E114.
22. Jorgensen JO, Rosenfalck AM, Fisker S, et al. Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study. Eur J Endocrinol. 2000;143(5):593-599.
23. Bentham J, Rodriguez-Arnao J, Ross RJ. Acquired growth hormone resistance in patients with hypercatabolism. Horm Res. 1993;40(1-3):87-91.
24. Udy AA, Baptista JP, Lim NL, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014;42(3):520-527.
25. Ulldemolins M, Rello J. The relevance of drug volume of distribution in antibiotic dosing. Curr Pharm Biotechnol. 2011;12(12):1996-2001.